Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.


TSXV:MPH - Post by User

Bullboard Posts
Comment by amp7on Mar 23, 2008 5:41pm
549 Views
Post# 14761659

RE: Re Lars Hoie

RE: Re Lars HoieGranted Hoie is fallible. Like us, he may have made a bet and crossed his fingers. He may be licking his financial wounds as a result. At $20 million plus, it’s a fairly deep cut. Unlike us, he has access to technical resources to assist him in evaluating MPH’s residual value. He may also be in a position to throw MPH a lifeline. He will no doubt take the time needed for a sober second look, but at least, like us, he has a vested interest in having MPH survive. In the meantime, MPH’s management has to drastically cut costs and look for financing in a very hostile credit environment. Not saying Hoie will necessarily be MPH’s white knight. Just suggesting that since he has not reported any sales on SEDI, his continued involvement should be classified as a small positive and these days, positives are hard to find. Perhaps the company comes up with a few more positives in April and shareholders begin to see a glimmer of hope. Either way, it’s going to take time to recover from this torpedo to MPH’s engine room.
Bullboard Posts